Inventiva Announces Results of its Mixed General Meeting
The biopharmaceutical company Inventiva has disclosed the voting results of its Mixed General Meeting held on November 27, 2025, according to its press release.
Voting Outcomes
According to Inventiva's press release, all resolutions presented at the Mixed General Meeting were adopted by the shareholders, except for the fifth resolution. This resolution, which had received an unfavorable recommendation from the Board of Directors, proposed to empower the Board to decide on capital increases reserved for members of a savings plan. The quorum for this meeting was 56.432%. Regarding the details of the votes, the first resolution was adopted with 89.783% in favor and 10.217% against, while the fifth resolution was rejected with 41.642% in favor and 58.358% against.
Ordinary and Extraordinary Resolutions
According to the results of the ordinary part, resolutions 1, 2, 3, and 6 were adopted. Resolution 6 particularly gathered 99.953% of favorable votes. For the extraordinary resolutions, resolution 4 was also adopted with 89.888% of votes in favor. However, resolution 5 was rejected, highlighting the shareholders' opposition to expanding the Board of Directors' powers concerning capital increases linked to the corporate savings plan.
Company Overview
Inventiva is a company specialized in developing therapies to treat steatohepatitis associated with metabolic dysfunction. The company is listed on Euronext Paris and the Nasdaq Global Market. Currently, its flagship product, Lanifibranor, is undergoing a Phase 3 clinical trial. The results of the Mixed General Meeting reflect a general approval from shareholders for most of the proposed strategies, except for those involving an expansion of the Board's powers regarding savings plans.
